Westphal Otto, Lindberg Anders
Göteborg Pediatric Growth Research Center, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
Acta Paediatr. 2008 Dec;97(12):1698-706. doi: 10.1111/j.1651-2227.2008.01053.x. Epub 2008 Oct 13.
To assess final height in children with growth hormone deficiency (GHD) treated with human recombinant growth hormone (GH).
Final height data for 401 Swedish children with idiopathic GHD and treated with GH, included in KIGS (Pfizer International Growth Database) between 1987 and spring 2006, were analysed retrospectively. Data were grouped according to sex, age and severity of GHD. Height at entry into KIGS, at the onset of puberty and near final height were analysed between groups.
Groups were heterogeneous for GHD, which ranged from partial to severe. For all groups, mean final height corrected for mid-parental height was within the normal Swedish height range. In patients with severe GHD, mean final height was almost identical to mean normal Swedish height. About 16% of patients showed disproportionality (short legs) at final height and were significantly shorter than other patients. The parents of these children also demonstrated short stature.
Children with idiopathic GHD receiving GH replacement therapy can achieve a final height that as a group is within the normal range and all achieve a height within their genetic potential.
评估接受重组人生长激素（GH）治疗的生长激素缺乏症（GHD）患儿的最终身高。
回顾性分析1987年至2006年春季纳入辉瑞国际生长数据库（KIGS）的401例接受GH治疗的瑞典特发性GHD患儿的最终身高数据。根据性别、年龄和GHD严重程度对数据进行分组。分析各亚组患儿进入KIGS时、青春期开始时及接近最终身高时的身高情况。
各亚组GHD严重程度不同，从部分缺乏到严重缺乏。所有亚组经父母身高中值校正后的平均最终身高均在瑞典正常身高范围内。重度GHD患儿的平均最终身高几乎与瑞典正常平均身高相同。约16%的患儿在最终身高时显示不成比例（腿短），且明显低于其他患儿。这些患儿的父母也身材矮小。
接受GH替代治疗的特发性GHD患儿的最终身高总体在正常范围内，且所有患儿的身高均在其遗传潜力范围内。
